Alimta

... Japan Today - News - Ministry to shorten study period on drug for asbestos-linked cancer - Japan's Leading International News Network Japan Today Newsfinder Friends America Today PREMIUM : SPONSORED LINKS Fly to Europe with Lufthansa Special offer from ¥70,000 Medical Insurance for Foreigners Wide coverage, few exclusions, low rates Monthly apartments in Tokyo From 80,000 yen including utilities GlobalHealth.jp - simply the best Health insurance for foreigners in Japan Getting 0% in a Japanese bank?

!

14-16% target returns + capital guarantees CARS Car Insurance in Japan?

AIU Insurance will help you HOUSING Serviced apartments in Tokyo The Serviced Apartments Pioneer Since 1974 Do you think torture of captured terrorist suspects is acceptable if it leads to information that might prevent further attacks or take out terrorist leaders?

YesNo What's your favorite style of curry?

"About 20 years ago, I used to go to a curry restaurant named Bolts." Middle-aged adults freak out Rich OLs a new and growing breed 'Enjo-kosai' continues to evolve Women still ailing with 'Yon-fluenza' Broken heart turned reporter to arson Last interview with Mishima surfaces Japan's male golfers in decline Intruder gives newscaster a fright Japanese really are forever young Japan's latest export - Sudoku The Russians are coming Olympics at Yoyogi Park?

No thanksBaker's story not all it appearedKin of dead soldiers back shrine visitsAbno...

... SF Jury Finds Chrysotile Asbestos Causes Rare Peritoneal Mesothelioma November 18, 2005 Home About Submit Press Release PR Firms Editors/Journalists Search Archives News Releases by Category News by Country News by MSA All News for Today Browse News by Day All Press Releases for November 18, 2005 SF Jury Finds Chrysotile Asbestos Causes Rare Peritoneal Mesothelioma Download this press release as an Adobe PDF document.

A jury awarded over $1.9 million to a 71–year–old retired sheet metal worker who developed peritoneal mesothelioma from his prior on–the–job exposure to asbestos.

San Francisco, CA (PRWEB) November 18, 2005 - A jury awarded over $1.9 million to a 71–year–old retired sheet metal worker, Genaro Garcia, who developed peritoneal mesothelioma from his prior on–the–job exposure to asbestos (Genaro Garcia and Dalia Garcia v.

Duro Dyne Corporation, SF Superior Court, #418098).

Peritoneal mesothelioma is an aggressive form of cancer that first attacks the membranes lining the stomach.

This fatal disease is almost always caused by asbestos exposure.

The defendant, Duro Dyne Corporation, is a former manufacturer and distributor of asbestos–containing flex HVAC duct connectors and duct sealer used for sheet metal duct connections.

Mr.

Garcia worked with Duro Dyne Corporation's asbestos–containing sheet metal products throughout his 48–year career, but was never advised to wear ...

... Breaking News: Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) BODY { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: #ececec; PADDING-BOTTOM: 0px; MARGIN: 0px; FONT: 85% Arial, Helvetica, sans-serif; PADDING-TOP: 0px } Log in Register Now UPDATED 11/14/2005 8:55:00 AM EST Contact Us Mary Ann Liebert, Inc.

About GEN Home In The News Breaking News Sticky Ends Online Current Issue New Products On The Web Past Issues Calendar of Events Classifieds View Listings Submit a Listing Web Resources Subscribe to GEN Reprints Advertise in GEN Media Kit Mailing List Rental Partnership Opportunities Editorial Editorial Calendar Meet the GEN Editors Gen database of Biotech Firms Home » In The News » Breaking News Breaking News Email article to a colleague Printer friendly version Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) 11/14/2005 7:58:00 AM EST Hana Biosciences (AMEX:HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, announced today positive interim data from an ongoing, multi-center Phase I clinical study evaluating single agent Talotrexin (PT-523) in relapsed or refractory advanced non-small cell lung cancer...